SCHEMBL3047529

SCHEMBL3047529

COc1ccc(N2CCN(c3ccc(N=C=O)cc3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
HTR3E A5X5Y0 1/20 0.51
HTR3B O95264 1/20 0.51
ADRB1 P08588 1/20 0.51
HTR3A P46098 1/20 0.51
HTR3D Q70Z44 1/20 0.51
HTR3C Q8WXA8 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
LMNA P02545 2/20 0.51
TSHR P16473 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 3/20 0.50
MAPT P10636 2/20 0.50
RAB9A P51151 2/20 0.50
DRD2 P14416 1/20 0.50
AKR1C3 P42330 1/20 0.49
SLC18A3 Q16572 1/20 0.48
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9380858 0.85 HTR3E (0.53) L3MBTL1HTR3EHTR3BADRB1HTR3A
SCHEMBL161063 0.84 CYP3A4 (0.50) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL519497 0.81 ALDH1A1 (0.56) HTR3ALMNATSHRSMN1; SMN2KMT2A
SCHEMBL12265053 0.81 L3MBTL1 (0.57) L3MBTL1HTR3EHTR3BADRB1HTR3A
SCHEMBL21466082 0.81 HTR3E (0.59) L3MBTL1HTR3EHTR3BADRB1HTR3A
SCHEMBL28599511 0.80 HTR3E (0.73) L3MBTL1HTR3EHTR3BADRB1HTR3A
SCHEMBL29656856 0.80 HTR3E (0.73) L3MBTL1HTR3EHTR3BADRB1HTR3A
SCHEMBL13246064 0.79 ESR2 (0.47) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL28954366 0.79 TRIM24 (0.52) L3MBTL1LMNATSHRSMN1; SMN2KMT2A
SCHEMBL28101787 0.79 LTA4H (0.48) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130237705-A1 METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES PETERSON JOHN R (US) 2013-09-12 US disclosed
US-8431699-B2 Method for manufacture of 2-oxoimidazolidines Vertichem Corporation (CA) 2013-04-30 US disclosed
US-8431699-B2 Method for manufacture of 2-oxoimidazolidines Vertichem Corporation (CA) 2013-04-30 US disclosed
WO-2010099518-A2 METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES THESIS CHEMISTRY, LLC (US) 2010-09-02 WO disclosed
WO-2010099518-A2 METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES THESIS CHEMISTRY, LLC (US) 2010-09-02 WO disclosed
US-20100222588-A1 Method for Manufacture of 2-Oxoimidazolidines THESIS CHEMISTRY, LLC (US) 2010-09-02 US disclosed
US-20100222588-A1 Method for Manufacture of 2-Oxoimidazolidines THESIS CHEMISTRY, LLC (US) 2010-09-02 US disclosed
US-20100222588-A1 Method for Manufacture of 2-Oxoimidazolidines THESIS CHEMISTRY, LLC (US) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237705-A1 METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES ODC1, NISCH, IMPDH2 L3MBTL1 4590/4885HTR3E 4513/4885HTR3B 3605/4885
US-20100222588-A1 Method for Manufacture of 2-Oxoimidazolidines ODC1, CBR3, CBR1 L3MBTL1 2067/4885HTR3E 4173/4885HTR3B 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.